BioSpace News Archive

CALQUENCE (acalabrutinib) is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

These data, presented at the 22nd biennial HEP DART meeting held in Kona, Hawaii, from Dec. 3-7, indicate that multiple doses of an RNAi-based therapy may lead to a host response that is sustained after therapy is concluded.

An option for an agreement extension will be evaluated, considered and negotiated by Tersus and Relevium, subject to the fulfillment of the two (2) year Agreement Terms.

- CIRM grant will support further development of Forty Seven Inc.'s CD47 antibody Hu5F9-G4 in an ongoing second trial for the treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome - [06-December-2017] MENLO PARK, Calif., Dec. 6, 2017 /PRNewswire/ -- Forty Seven Inc., a clinical-stage company focused on developing the next generation of transformati

The license, coupled with the existing license through the Broad Institute of MIT and Harvard, allows Charles River to offer custom in vivo and in vitro genome editing.

Radient Technologies is pleased to announce the senior appointments of Jim Seethram and Dr. Tomasz Popek to key roles in its growth plans.

Neogen announced today that Ed Bradley has advised the company of his intentions to retire to pursue his personal interests.

These research projects are for studies of an early stage imaging agent (MK-6240) to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain.

When granted, these new patents will expand CytRx’s intellectual property estate and the Company will own worldwide rights for each.

In her newly expanded role, Batta will be responsible for the successful execution of the company’s commercial strategy both organically and through strategic alliances for both the Fertilome test and the Polaris® analytics platform, as well as helping to evaluate opportunities for international expansion.